deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT01171807

Erythrocytes-Mediated Delivery Of Dexamethasone 21-Phosphate In Steroid-Dependent Ulcerative Colitis (Crocodex)

Dexamethasone Intra-Erythrocyte Therapy in Patients With Chron's Disease or Ulcerative Colitis

Sponsor: Casa Sollievo della Sofferenza IRCCS

Interventions Dex 21-P Placebo
Updated 6 times since 2017 Last updated: Sep 17, 2024 Started: Jul 22, 2003 Primary completion: May 15, 2007 Completion: May 15, 2007
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Ulcerative Colitis, this trial is completed. The trial is conducted by Casa Sollievo della Sofferenza IRCCS and has accumulated 6 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotUnknown Status~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotUnknown Status~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshotUnknown~Oct 2024 – present · 21 months · monthly snapshotCompleted

Change History

6 versions recorded
  1. Oct 2024 — Present [monthly]

    Completed PHASE2

    Status: UnknownCompleted

  2. Sep 2024 — Oct 2024 [monthly]

    Unknown PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown StatusUnknown

  4. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE2

Show 1 earlier version
  1. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE2

    First recorded

Jul 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Casa Sollievo della Sofferenza IRCCS
  • Quince Therapeutics S.p.A.
Data source: Quince Therapeutics S.p.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations